Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893040 | 0.84 | ALDH1A1 (0.49) | ALDH1A1KDM4ESMN1; SMN2TDP1HTT | |
| SCHEMBL12259083 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2TDP1HTT | |
| SCHEMBL1911484 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2TDP1HTT | |
| SCHEMBL12258816 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2TDP1HTT | |
| SCHEMBL23717395 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2TDP1HTT | |
| SCHEMBL7294395 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4ESMN1; SMN2TDP1HTT | |
| SCHEMBL13239678 | 0.77 | KDM4E (0.57) | ALDH1A1KDM4ESMN1; SMN2TDP1ATM | |
| SCHEMBL8259396 | 0.77 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2TDP1HTT | |
| SCHEMBL14874211 | 0.76 | KDM4E (0.63) | ALDH1A1KDM4ESMN1; SMN2TDP1ATM | |
| SCHEMBL8438204 | 0.76 | KDM4E (0.63) | ALDH1A1KDM4ESMN1; SMN2TDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | YALE UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | DUSP5, DUSP4, DUSP6 | ALDH1A1 1762/4885KDM4E 902/4885SMN1; SMN2 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.